Our work with the pharmaceutical industry
Our mission is to create a world where being born with cystic fibrosis (CF) no longer means a lifelong burden of care and an early death, when everyone living with the condition will be able to look forward to a long, healthy life.
To support our vital work, we take funding from a range of sources, including pharmaceutical companies.
We assess all funding relationships to ensure that they do not risk the help we provide, our independence or our reputation. All funding arrangements are disclosed in our annual report and accounts and must meet the requirements of our ethical fundraising policy, which is overseen by our Trustees. We do not accept payment to promote or recommend specific products and treatments to individuals or influence prescribing practices for specific branded medicines.
Funding from pharmaceutical companies has supported:
- The UK Cystic Fibrosis Registry – covering the cost of reporting to regulators on the safety and effectiveness of CF medicines, including providing data entry grants to CF care centres
- The Clinical Trials Accelerator Platform – a UK-wide initiative to increase participation in and access to CF clinical trials
- The Venture and Innovation Awards – supporting transformational and innovative research projects by providing financial support and bringing funding into the field of CF from external sources, including the pharmaceutical industry
- The UK Cystic Fibrosis Conference – an event for healthcare professionals and people affected by CF, dedicated to all aspects of clinical care and research in the field of cystic fibrosis
Research we fund
We fund research to tackle some of the most pressing issues in CF today. Find out how your donations are making a difference.
What is CF?
Cystic fibrosis, or CF, affects the lungs, digestive system and other organs. There are around 11,000 people living with it in the UK.
Get in touch with us to speak to someone on our Helpline, find out about an event or speak to our press team.